Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neostigmine | 2 | 2021 | 8 | 0.350 |
Why?
|
| Hazardous Substances | 1 | 2009 | 12 | 0.350 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2021 | 26 | 0.340 |
Why?
|
| Postoperative Complications | 6 | 2021 | 2235 | 0.340 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 301 | 0.320 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 513 | 0.300 |
Why?
|
| Environment | 1 | 2009 | 346 | 0.300 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 331 | 0.290 |
Why?
|
| Autistic Disorder | 1 | 2009 | 168 | 0.290 |
Why?
|
| Quality Improvement | 4 | 2021 | 963 | 0.230 |
Why?
|
| Dementia, Vascular | 1 | 2022 | 20 | 0.210 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 30 | 0.200 |
Why?
|
| Surgical Procedures, Operative | 2 | 2015 | 215 | 0.200 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2021 | 16 | 0.200 |
Why?
|
| Postoperative Hemorrhage | 1 | 2021 | 79 | 0.180 |
Why?
|
| Robotics | 1 | 2021 | 83 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 89 | 0.180 |
Why?
|
| Inpatients | 1 | 2023 | 388 | 0.180 |
Why?
|
| Otolaryngology | 1 | 2021 | 84 | 0.170 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 60 | 0.170 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 29 | 0.170 |
Why?
|
| Ketorolac | 1 | 2018 | 18 | 0.170 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 22 | 0.170 |
Why?
|
| Machine Learning | 1 | 2022 | 331 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2021 | 814 | 0.160 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 136 | 0.160 |
Why?
|
| Tennessee | 4 | 2021 | 44 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2018 | 132 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 234 | 0.150 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2016 | 9 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2021 | 417 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2016 | 39 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2023 | 12978 | 0.140 |
Why?
|
| Neuromuscular Blockade | 1 | 2016 | 23 | 0.140 |
Why?
|
| Patient Handoff | 1 | 2016 | 27 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2021 | 521 | 0.140 |
Why?
|
| Transitional Care | 1 | 2016 | 38 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 304 | 0.140 |
Why?
|
| Palliative Care | 1 | 2022 | 629 | 0.140 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 41 | 0.130 |
Why?
|
| Anesthesia | 1 | 2016 | 120 | 0.130 |
Why?
|
| Infection Control | 1 | 2015 | 135 | 0.120 |
Why?
|
| Cross Infection | 1 | 2015 | 205 | 0.110 |
Why?
|
| tau Proteins | 2 | 2023 | 78 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2015 | 545 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2015 | 635 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 610 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 523 | 0.100 |
Why?
|
| Biomarkers | 3 | 2023 | 3588 | 0.090 |
Why?
|
| Amyloid beta-Peptides | 2 | 2023 | 200 | 0.090 |
Why?
|
| Humans | 19 | 2023 | 118974 | 0.090 |
Why?
|
| Length of Stay | 3 | 2021 | 1032 | 0.090 |
Why?
|
| Middle Aged | 10 | 2022 | 27617 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 325 | 0.090 |
Why?
|
| Glutathione Disulfide | 1 | 2009 | 29 | 0.090 |
Why?
|
| Neoplasms | 1 | 2023 | 2179 | 0.090 |
Why?
|
| Mercury | 1 | 2009 | 29 | 0.090 |
Why?
|
| Sulfates | 1 | 2009 | 47 | 0.080 |
Why?
|
| Cysteine | 1 | 2009 | 184 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2022 | 5116 | 0.070 |
Why?
|
| Adult | 7 | 2022 | 31512 | 0.070 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 251 | 0.070 |
Why?
|
| Diastole | 1 | 2005 | 145 | 0.060 |
Why?
|
| Systole | 1 | 2005 | 168 | 0.060 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2005 | 62 | 0.060 |
Why?
|
| Female | 10 | 2022 | 61565 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 1231 | 0.060 |
Why?
|
| United Kingdom | 1 | 2023 | 236 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2018 | 634 | 0.060 |
Why?
|
| Male | 9 | 2022 | 57801 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2023 | 249 | 0.050 |
Why?
|
| Neuropathology | 1 | 2022 | 4 | 0.050 |
Why?
|
| Placenta Growth Factor | 1 | 2022 | 25 | 0.050 |
Why?
|
| Autopsy | 1 | 2022 | 89 | 0.050 |
Why?
|
| Goals | 1 | 2023 | 167 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2023 | 306 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2005 | 468 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 2424 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 114 | 0.050 |
Why?
|
| Colectomy | 1 | 2021 | 84 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 18480 | 0.050 |
Why?
|
| Risk Factors | 3 | 2021 | 9000 | 0.050 |
Why?
|
| Aged | 4 | 2021 | 19657 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2022 | 3057 | 0.050 |
Why?
|
| Urinary Catheterization | 1 | 2019 | 24 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 688 | 0.040 |
Why?
|
| Urinalysis | 1 | 2019 | 68 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 176 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 527 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 299 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 160 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 761 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 422 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 1527 | 0.040 |
Why?
|
| Reoperation | 1 | 2018 | 557 | 0.040 |
Why?
|
| Causality | 1 | 2016 | 109 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2018 | 983 | 0.030 |
Why?
|
| Child | 2 | 2019 | 19129 | 0.030 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2015 | 45 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2009 | 9491 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 853 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1810 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1785 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 262 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 709 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2012 | 110 | 0.020 |
Why?
|
| Pneumonia | 1 | 2016 | 592 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 6471 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1865 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 845 | 0.020 |
Why?
|
| United States | 2 | 2015 | 12555 | 0.020 |
Why?
|
| Colforsin | 1 | 2005 | 55 | 0.020 |
Why?
|
| Endocardium | 1 | 2005 | 31 | 0.020 |
Why?
|
| Pericardium | 1 | 2005 | 50 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6561 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 192 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1094 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2015 | 9342 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 10793 | 0.010 |
Why?
|